AstraZeneca Pays $34 Million to Settle Texas Medicaid Kickback Claims
AstraZeneca agreed to pay $34 million to resolve allegations brought by the Texas Attorney General that the company paid kickbacks to improperly influence prescriptions reimbursed by Texas Medicaid. The settlement resolves claims that the pharmaceutical manufacturer violated anti-kickback statutes through payments that influenced prescribing behavior for drugs covered under the state's Medicaid program. The settlement does not include an admission of liability but ends the state's enforcement action against the company.
This settlement underscores state-level enforcement of anti-kickback provisions and signals continued scrutiny of pharmaceutical manufacturer relationships that may inflate Medicaid drug spending.
Pharmacy · Managed Care
You might also like